Onxol Side Effects
Generic name: paclitaxel
Note: This document contains side effect information about paclitaxel. Some of the dosage forms listed on this page may not apply to the brand name Onxol.
Some side effects of Onxol may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to paclitaxel: intravenous solution
Along with its needed effects, paclitaxel (the active ingredient contained in Onxol) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking paclitaxel:More common
- Black or tarry stools
- blurred vision
- burning, numbness, tingling, or painful sensations
- cough or hoarseness with fever or chills
- dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
- feeling of warmth
- fever or chills
- lower back or side pain
- painful or difficult urination
- pale skin
- redness of the face, neck, arms, and occasionally, upper chest
- shortness of breath
- skin rash or itching
- sore throat
- troubled breathing with exertion
- ulcers, sores, or white spots in the mouth
- unsteadiness or awkwardness
- unusual bleeding or bruising
- unusual tiredness or weakness
- weakness in the arms, hands, legs, or feet
- Blood in the urine or stools
- difficult or labored breathing
- pinpoint red spots on the skin
- shortness of breath (severe)
- slow heartbeat
- tightness in the chest
- blue lips, fingernails, or skin
- difficult or troubled breathing
- fast heartbeat
- irregular, fast or slow, or shallow breathing
- sudden shortness of breath
Some side effects of paclitaxel may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common
- Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
- cracked lips
- difficulty with swallowing
- hair loss
- nausea or vomiting
- numbness, burning, or tingling in the hands or feet
- pain in the joints or muscles, especially in the arms or legs
- thinning of the hair
For Healthcare Professionals
Applies to paclitaxel: intravenous solution
Hematologic side effects including bone marrow suppression have been the major dose-limiting toxicity. Neutropenia less than 2,000 cells/mm3 (90%) and less than 500 cells/mm3 (52%), is the most important hematological toxicity. Neutropenia has been both dose and schedule dependent, and generally rapidly reversible. The onset of neutropenia generally occurs after 8 to 10 days and recovery generally occurs after 15 to 21 days. Neutropenia does not appear to increase with cumulative exposure, nor to be more frequent or severe for patients previously treated with radiation therapy. Leukopenia less than 4,000 cells/mm3 (90%) and less than 1,000 cells/mm3 (17%), thrombocytopenia less than 100,000 cells/mm3 (20%) and less than 50,000 cells/mm3 (7%), and anemia less than 11 g/dl (78%) and less than 8 g/dl (16%) have been reported. Infections (30%), bleeding (14%), red cell transfusions (25%) and platelet transfusions (2%) have been reported. A case of paclitaxel-induced sickle cell crisis has also been reported.
Fever (12% of all treatment courses) has been reported. Fatal infectious episodes (1%) including sepsis, pneumonia and peritonitis have been reported.
Bleeding episodes (4% of all courses and 14% of all patients) have been reported. Most of the episodes were localized.
Hypersensitivity side effects (41%) including severe reactions (2%) have been reported. The most frequent symptoms observed during the severe reactions were dyspnea, flushing, chest pain, and tachycardia. Minor hypersensitivity reactions consisted mostly of flushing (28%), rash (12%), hypotension (4%), dyspnea (2%), tachycardia (2%), and hypertension (1%). Three patients with transient pulmonary infiltrates caused by hypersensitivity reactions (after receiving treatment with paclitaxel (the active ingredient contained in Onxol) and carboplatin) have been reported. A case of pneumonitis responsive to high-dose corticosteroids and a case of bullous fixed drug eruption have also been reported.
The frequency and severity of hypersensitivity reactions were not affected by the dose or schedule of administration. Severe symptoms have primarily been reported to occur within the first hour of the infusion.
Single dose intravenous dexamethasone can be used in combination with appropriated ancillary medications to prevent paclitaxel-related hypersensitivity reactions.
The manufacturer further states that abnormal ECG readings have been reported in 23% of all patients receiving paclitaxel (the active ingredient contained in Onxol) and in 14% of the patients with normal baseline ECGs. The most frequently reported ECG modifications were nonspecific repolarization abnormalities, sinus bradycardia, sinus tachycardia and premature beats.
Cardiovascular side effects have included vital sign changes including bradycardia (3%) and hypotension (12%) during the first 3 hours of infusion as stated by the manufacturer. Significant cardiovascular events (1%) including syncope, rhythm abnormalities, hypertension and venous thrombosis have also been reported. A report from the Johns Hopkins oncology center stated that asymptomatic sinus bradycardia occurred in up to 29% of patients in phase 2 trails, and that other cardiac disturbances including atrioventricular conduction and bundle branch blocks, ventricular tachycardia, and possible ischemic manifestations had been reported (3%). A case of fatal myocardial infarction potentially induced by paclitaxel has also been reported.
Nervous system side effects including neurotoxicity, primarily including peripheral neurosensory manifestations (60%), have generally been mild to moderate in severity. However, severe symptoms (3%) have also been reported. Other serious neurologic events (less than 1%) have been reported including grand mal seizures, syncope, ataxia, neuroencephalopathy and autonomic neuropathy resulting in paralytic ileus. Disturbances of the optic nerve (19%) have also been reported.
The frequency and severity of neurologic manifestations have been dose dependent and cumulative. One study found that although the neurotoxicity was frequent, it remained mild or subclinical up to at least 1400 mg/m2 administered over 8 cycles.
Peripheral neuropathy may appear within 24 to 72 hours when high doses are administered. The frequency of peripheral neuropathy also has been reported to have increased with cumulative dose. It usually presents as a "stocking-and-glove" numbness and paresthesia.
At least 3 cases of phantom limb pain associated with paclitaxel use have been reported.
Gastrointestinal side effects including nausea and vomiting (52%), diarrhea (38%) and mucositis (31%) have been reported. Intestinal obstruction, intestinal perforation and ischemic colitis have been reported rarely. Three cases of pancreatitis have also been reported.
Gastrointestinal effects can generally be treated with standard antiemetic antidiarrheal therapy and dietary changes.
Mucositis occurs most frequently in patients receiving high doses. It is schedule-dependent, occurring more frequently with 24 and 96 hour infusions.
The author of one of the case reports of pancreatitis suggested that it was the companion agent, cremophor that was the cause, rather than the paclitaxel itself.
Prolonged exposure to paclitaxel (the active ingredient contained in Onxol) has not been associated with cumulative hepatic toxicity.
Hepatic side effects including elevations in bilirubin (7%), alkaline phosphatase (22%) and AST (SGOT) (19%) have been reported in patients with normal baseline levels. Hepatic necrosis and hepatic encephalopathy leading to death have been reported rarely. A case of fatal hepatic coma has also been reported.
Renal side effects including edema have been reported in 21% of all patients receiving paclitaxel (the active ingredient contained in Onxol) and 17% of patients without baseline edema. Severe edema has been reported in 1% of patients.
Dermatologic side effects including transient skin changes due to hypersensitivity reactions and skin abnormalities related to radiation recall have been reported. Alopecia (87%) and cumulative loss of body hair have also been reported. Some reports suggest that paclitaxel (the active ingredient contained in Onxol) may cause vesicant reactions when extravasated. Nail changes including changes in pigmentation or discoloration of the nail bed have been reported (2%). Two cases of cutaneous lupus erythematosus and one case of systemic lupus erythematosus have been reported. Two cases of scleroderma-like reactions have been reported. A case of paclitaxel administration via a central vein producing a recall reaction at a site of prior paclitaxel extravasation has also been reported. A case of severe mucocutaneous toxicity and a case of cutaneous systemic sclerosis have been reported.
Alopecia usually begins 1 to 2 weeks after treatment and is usually reversible.
Respiratory side effects including radiation recall pneumonitis have been reported.
Musculoskeletal side effects including myalgia and/or arthralgia (60%), including severe symptoms (8%) have been reported.
Symptoms were usually transient, occurred two or three days after drug administration and resolved within five to seven days. Symptoms are more frequent and severe in patients receiving doses greater than 200 mg/m2.
Injection site reactions, including reactions secondary to extravasation, were usually mild and consisted of erythema, tenderness, skin discoloration, or swelling at the injection site.
Local side effects have included injection site reactions. Phlebitis has been reported rarely.
Other side effects including cellulitis have been reported rarely.
More Onxol resources
- Onxol Prescribing Information (FDA)
- Onxol MedFacts Consumer Leaflet (Wolters Kluwer)
- Onxol Advanced Consumer (Micromedex) - Includes Dosage Information
- Paclitaxel Prescribing Information (FDA)
- Paclitaxel Professional Patient Advice (Wolters Kluwer)
- Paclitaxel Monograph (AHFS DI)
- Taxol Consumer Overview
- Taxol Prescribing Information (FDA)
- paclitaxel MedFacts Consumer Leaflet (Wolters Kluwer)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.